Molecular Target Drug for Cervical Cancer

Cervical cancer is the fourth most common malignant tumor in women worldwide in terms of incidence and mortality. Although cervical cancer is a disease whose morbidity and mortality rates have decreased over the past few decades in some developed countries due to the widespread use of cervical cancer screening and HPV vaccination with the introduction of HPV testing, no significant progress has been made in terms of treatment options. Chemotherapy, represented by platinum-based drugs such as cisplatin, is still the mainstay of treatment, but its efficiency is low, and new drugs, such as molecularly targeted therapies, are urgently needed. With the development of molecular biology and genomic medicine, molecular-targeted therapeutics have made groundbreaking progress in many cancer tumors. Effective therapies such as angiogenesis inhibitors and immune checkpoint inhibitors have been developed for cervical cancer. This review summarizes new targeted therapeutics in clinical trials to treat cervical cancer. Furthermore, it aims to summarize novel agents with a focus on their therapeutic efficacy in preclinical studies.